Powered by: Motilal Oswal
2026-09-03 11:39:33 am | Source: Accord Fintech
Amanta Healthcare touches roof on commencing production at new SteriPort facility
Amanta Healthcare touches roof on commencing production at new SteriPort facility

Amanta Healthcare is currently trading at upper  limit of Rs. 191.00, up by 3.70 points or 1.98% from its previous closing of Rs. 187.30 on the BSE.

The scrip opened at Rs. 191.00 and has touched a high and low of Rs. 191.00 and Rs. 191.00 respectively. So far 5045 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 205.10 on 24-Aug-2026 and a 52 week low of Rs. 93.10 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 191.00 and Rs. 183.50 respectively. The current market cap of the company is Rs. 741.64 crore.

The promoters holding in the company stood at 63.80%, while Institutions and Non-Institutions held 13.35% and 22.85% respectively.

Amanta Healthcare has commenced production at its new SteriPort facility situated at Kheda campus. SteriPort has unique features like absolute sterility, superior transparency and far more tensile strength. This enhances the container integrity by manifold. It’s two-port system ensures leakproof IV administration and medication. SteriPort also demonstrates superior compatibility with potent drugs especially in Onco and Intensive Care.

The new facility incorporates technological advancements and higher degree of automation primarily aimed at reduced human interference, enhanced quality assurance and patient safety. The brownfield facility is expected to scale up the operational and financial efficiency, resulting into EBITDA margin expansion.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here